Today classification of drug candidates on the Biopharmaceutics Classification System (BCS) has become an important issue in pharmaceutical researches. In this work, we provide a potential in silico approach to predict this system using two separately classification models of Dose number and Caco-2 cell permeability. 18 statistical linear and nonlinear models have been constructed based on 803 0-2D Dragon and 126 Volsurf+ molecular descriptors to classify the solubility and permeability properties. The voting consensus model of solubility (VoteS) showed a high accuracy of 88.7% in training and 92.3% in test set. Likewise, for the permeability model (VoteP), accuracy was 85.3% in training and 96.9% in test set. A combination of VoteS and VoteP appropriately predicts the BCS class of drugs (overall 73% with class I precision of 77.2%). This consensus system predicts the BCS allocations of 57 drugs appeared in the WHO Model List of Essential Medicines with 87.5% of accuracy. A simulation of a biopharmaceutical screening assay has been proved in a large data set of 37,377 compounds in different drug development phases (1, 2, 3 and launched), and NMEs. Distributions of BCS forecasts illustrate the current status in drug discovery and development. It is anticipated that developed QSPR models could offer the best estimation of BCS for NMEs in early stages of drug discovery.
Introduction
After almost 20 years of the introduction and exploration of the Biopharmaceutics Classification System (BCS), it has gained a major impact on the regulation and development of immediate release (IR) solid oral drug products [1, 2] . Based on the principal factors that determine the rate and extent of drug absorption, the BCS provides a scientific framework for classifying drug substances into one of four categories. According to BCS, IR solid oral dosage forms are categorized as having either rapid or slow in vitro dissolution, and then classified based on aqueous solubility and intestinal permeability of the active pharmaceutical ingredient (API) [1] . This system has been formally adopted by the US FDA [3] , the European agency EMEA [4] and the World Health Organization (WHO) [5] as a technical standard for waiving BE test requirements for oral drugs. A recent study of the economic impact of granting biowaivers for class I and III BCS demonstrated an impressive saving annual expenditure on running BE studies, being more than 120 million dollars between the two classes [6] . Because it avoids unnecessary drug exposures to healthy subjects, while maintaining the high public health standard for therapeutic equivalence, the BCS is, without doubt, a potential tool for speeding up and reducing the cost of drug development.
There is a continuing effort worldwide to detect, in the early discovery, the possible BCSbased biowaiver candidates, e.g. BCS class I drugs [7] . One of the common strategies is based on BCS provisional classification in which the drugs are classified by two sources: dose related solubility data (Dose number, Do) and estimated human absorption data, i.e. in vitro permeability (usually determined by the Caco-2 cell cultured method) [3, 8] , or simple in silico partition coefficient calculation [9] . In this regard, in silico approach presents the two most important advantages: (i) provides a flexible approach that can be applied in different stages of drug development with different purposes, and (ii) allows estimating the BCS classes of new molecular entities (NMEs) without knowledge of therapeutic dosage. Definitely, with respect to experimental methods, computational approaches are cost-saving and no sample requirement methods.
However, up to now, robust in silico approach, i.e. Quantitative Structure-Activity/Property Relationships (QSAR/QSPR) modeling, has not been explored sufficiently in the BCS studies. Based on published findings [10] , and to respond to the rising need of early identification of possible biowaiver drugs, in this work, we attempt to develop robust QSPR models to classify the solubility and permeability terms that compose the BCS (Figure 1 ). These models were rigorously validated on various published BCS class drug sets [5, 9, [11] [12] [13] and the feasibility of performing PBC prediction in early drug discovery is discussed. http://sciforum.net/conference/mol2net-1 Figure 1 . Summary scheme of current in silico study
Results and Discussion
In 2004, a number of 123 orally administered drugs on the World Health Organization (WHO) Essential Medicine List (EML) were initially classified into BCS [9, 11] . Later, 200 oral drug products in the United States, Great Britain, Spain, and Japan were classified based on published solubility data and permeability data estimated by calculated log P [12] . Recently, increasing attention has been turned out for determining the Provisional Biopharmaceutical location of orally administered immediaterelease (IR) drug products using different estimated gastrointestinal permeability, such as partition coefficients (log D and log P), molecular surface area (PSA) or other in vitro permeability.[14-17] It has been emphasized that the distribution of BCS class I, II, III, and IV in each classification are quite different. In this report, taking advantage of the availability of experimental in vitro Caco-2 cell data a Provisional Biopharmaceutical Classification (PBC) of 322 oral drug products gathered from literature was performed. To our knowledge, it is the largest data set for such classification. Classifications of current data are described in [7] .
Physicochemical profiling of PBC. It is very useful to analyze the similarity between physicochemical spaces characterized by PBC classes, especially for developing computational predictions of current PBC and further BCS. Thus, six commonly used physicochemical parameters were calculated by Dragon and Volsurf+ for this analysis: [18, 19] molecular weight (MW), polar surface area (PSA), Mlog P, log D6, log D7.5, total number of hydrogen bond donors and acceptors (nHA+B), number of free rotatable bonds (RBN), and estimated ionization states. The average and median values of maximum dose strength (Dmax) as well as Caco-2 Papp were also analyzed for each class.
Unsurprisingly, class II drugs display the highest lipophilicity, while class III and IV are more hydrophilic. Class I drugs represent a balanced physicochemical profile even though they tend to be more lipophilic. In general, only the hydrogen bonding term is fairly different from one class to another. There is certain physicochemical similarity between class I and II (Mlog P, log D at basic medium), class III and IV (nHA+B, PSA), or class II and III (MW), etc. Values of Dmax do not present any trend. It is demonstrated that poor bioavailability is more likely when the compounds violate two or more of the Lipinski's rules (Ro5): (i) log P <5, (ii) MW< 500, (iii) HBD (hydrogen bond donors) < 5, and (iv) HBA (hydrogen bond acceptors) < 10.
[20] Current data was collected mostly among successful drugs. Then, it is easy to understand that many of them (>95%) passed the Ro5.
Computational models to predict PBC class from chemical structures. Solubility and Caco-2 permeability were modeled independently. The final computational PBC classification was Mol2Net, 2015, 1(Section B), pages 1-11, Proceeding 4 http://sciforum.net/conference/mol2net-1 achieved using two voting consensus (permeability and solubility) systems. QSPR models obtained by different statistical techniques for each property are described below.
Solubility modeling. Three model series were obtained using LDA, QDA and BLR. Different molecular descriptors (MDs) were used for building QSPR models. From every model series constructed with every technique, the best one was selected (detailed comparisons are described in supplement documents). Table 1 summarizes the mathematical equations and performances of the three best models for PBC solubility prediction.
Permeability modeling. The same procedure was carried out to select the best classifiers for PBC permeability class. Table 2 displays the relevant information of permeability models.
Classifications of four PBC classes. The two obtained voting models were finally combined to estimate the four PBC classes of the data (322 compounds). Table 3 displays the confusion matrix of this consensus system. A good overall accuracy of 73.0 % was obtained by this system..
Analysis of molecular descriptors (MDs). Interestingly, the PBC solubility and permeability terms are well described using a small set of MDs. It is important to note that there are some MDs directly related to polarizability and dispersion forces within molecules (nCp, nCt), molecular size (nR10, P_VSA_v_3), lipophilicity and hydrophobicity (BLTD48, CATS2D_04_AL, CMC-50), and especially, the polar, chargeable and hydrogen bond forming capacity (A, Me, nO, nArC=N, NssNH, LgD5) . Beside, rule based MDs, which represent common physicochemical combination trends of known drug-like and lead-like dataset, [21, 22] On the other hand, the ionization state (GATS2s, P_VSA_s_6, nRNR2), molecular size (GATS2m, nFuranes, C-016) and hydrogen bond donor and acceptor regions (nRCOOH, nRNR2, nC=N-N<, CATS2D_03_DD, CATS2D_07_D, CATS2D_08_AP, SAdon, WN2 etc.) are well correlated with Caco-2 permeability. The ADME descriptor CACO2 was selected two times in permeability models. Please note that numeric values of this variable are result of partial least square (PLS) discriminant analysis developed by Zamora et al. [24] Unfortunately, the use of this descriptor does not provide precise knowledge of descriptor impacts on PBC permeability class. Regulatory validation and applications of in silico PBC models. A robust forecast of PBC class is very useful in early drug discovery. Especially, for many NMEs whose therapeutic dose-ranges are not available in preclinical stages. This is also important for estimating possible BCS memberships, since there is a great correspondence between proposed PBC and BCS cited in regulatory guidelines [5] . 
Mathematical equations
CLASS Do (+/-) = -1.59 -0.54×PˍVSAˍvˍ3 + 0.80×nArC=N + 0.65×C-005 -0.84×CATS2Dˍ04ˍAL + 0.79×DLSˍ04 + 4.51×ID3 + 0.28×A -0.41×LgD5 (S1) N = 257 λ = 0.60 D 2 = 2.74 F = 25.61 p < 0.0001 CLASS Do (+/-) = -0.36 -0.90×Me -1.40×nCt -0.79×NssNH + 1.22×BLTD48 + 0.87×DLSˍ04 -0.82×CMC-50 -1.86×nArC=N×N-067 + 0.41×N-067×NssNH -0.73×Me×CMC-50 + 0.51×nR10 2 (S2) N = 257 λ = 0.59 D 2 = 2.88 p < 0.0001 Ln (P+/P-) = 2.63 -0.59×nCp + 4.44×nArC=N + 0.20×H-052 + 1.82×N-067 -1.32×NssNH + 1.09×BLTD48 + 4.58×LDSˍ04 -1.38×CMC-50 -0.38×nO(
Biopharmaceutical Screening Simulations
Finally, a large database of drugs, clinical and non-clinical trial compounds was subjected to computational prediction using in silico PBC consensus model. A total number of 37,202 compounds were analyzed (Figure 2) . Recently, this database was classified by in silico BDDCS consensus models to estimate the distribution of BDDCS class. [10] In contrast to that study, obtained models here are employed for comparing the predictions and then making a round estimation of the distribution of BCS class. It is important to note that some compounds obtained non-conclusive-classification due to Mol2Net, 2015, 1(Section B), pages 1-11, Proceeding 6 http://sciforum.net/conference/mol2net-1 their condition of outliers of Ads. 1699 compounds (4.6% of prediction data) are classified as I/II, I/III, II/IV, and III/IV. Most of them (1512 compounds) are low-activity (W6) and
high-activity (W9) compounds.
[10] Especially, 29 compounds could not be classified by in silico models. Among those conclusively predicted as PBC class I, II, III and IV, there exists similar proportion between launched and clinical phase 3 drugs, between clinical phases 1 or 2 drugs and W6 or W9 compounds.
As can be appreciated from Figure 3 , more than 40% of drugs and phase 3 are similar to PBC class I. The phase 3 compounds similar to PBC class II significantly overcome the PBC class III but for drugs, their percentage become similar. Compounds classified as PBC class IV take the minimal proportion in the two drug sets (7-8% [29] For drugs that are not included in these documents or exist in different market presentations, the first introduced strengths were revised and used as highest dosages. Doses in mg/kg were transformed into mg assuming 70Kg as body weight. Dose Number Calculations. The dose number (D0) was calculated using the following equation
where, M0 is the highest dose strength (mg), S is the aqueous solubility (mg/mL) under conditions mentioned above and water volume V0 is assumed to be 250 mL. [1, 9] Drugs with D0 ≤ 1 were classified as high-solubility drugs. Conversely, drugs with D0 > 1 were assigned as low solubility drugs.[9] Permeability Estimations. In this work, in vitro Caco-2 cell permeability is used to classify drug according to BCS. For this purpose, we take advantage of our previous research where an extensive literature survey of this kind of data was processed.
[30] Besides, we have adopted the same method proposed by Kim et al., [31] taking the average permeability value of Metoprolol (average apparent permeability Papp = 20×10 -6 cm/s) for benchmarking the high permeability class boundary. Due to the large revised literature, the mean values were listed, excluding those laid outside of the mean±2SD (standard deviation) ranges. Additionally, available data obtained on both directions apical to basolateral (Papp, A-B) and viceversa (Papp, B-A) were taken into account. Computational methods. Taking all above together, in this work efforts have been made to establish really useful statistical predictors for BCS classes of NMEs based on two separate model series of dose number and Caco-2 cell permeability. To attain this purpose, the following computational procedures should be considered:
(i) suitably computing physicochemical and molecular descriptors, (ii) rational selection of training and test sets, (iii) establishment of modeling strategy and appropriated variable selection, and (iv) ascertainment of BCS predictions for NMEs in the context of regulatory statements. Molecular descriptor calculations. 803 simple (0-2D) descriptors belonging to 29 families implemented in Dragon software version 6.0, [19] and 126 molecular descriptors in VolSurf+ version 1.0.4 [18] were calculated. Model building and feature selection. Three statistical classification algorithms were applied in order to detect all possible (linear or nonlinear) relationships between solubility/permeability and computed parameters:
LDA (Linear Discriminant Analysis), QDA (Quadratic Discriminant Analysis) and BLR (Binary Logistic Regression).
Performances of models were evaluated using false positive rate (FPr), true negative rate (TN, for specificity), true positive rate (TP, for sensitivity), Matthews Correlation Coefficient (MCC) and predictive accuracy, as defined below: 
For reliable predictions of these three external datasets, it is important to consider all applicability domains (ADs) defined by the chemical spaces of the training set. There are many approaches for AD estimation.
[32] Here, the leverage approach, a geometric method commonly used for QSAR problems, was employed. The leverage of a compound in the original variable space is defined as hi = [X(X'X) -1 X'], where X is the descriptor matrix derived from the training set descriptor values. The warning leverage (h*) is defined as h*=3(p+1)/n, where n is the number of training compounds, and p is the number of predictor variables [32] . Compounds with hi > h* were observed to reveal their influence on classification performance. It is not necessary to exclude them from predictions although they appear to be outside AD. However, compounds are considered to be outliers if they lay outside the ±3 standardized residual (δ) range [32] . 
Conclusions
In this report, a systematic study was carried out in order to standardize a BCS-based provisional classification of 322 drugs and develop computational predictions of BCS class for NMEs. It is of great interest to assign as soon as possible the probable BCS class of a drug candidate. By using extensively revised references of solubility and in vitro Caco-2 permeability, a very commonly used preclinical assay in pharmaceutical industry, a better in vivo BCS classification of drugs is anticipated. Consequently, the classification results in this study display a high concordance with BCS classification of common regulatory authorities (WHO, FDA). Other classification schemes were compared with PBC. Large additional information concerning the BCS classification of current data was analyzed in order to identify advantages as well as limitations when using PBC. As an attempt to develop QSPR models able to predict the PBC class, it was demonstrated the possibility of screening NMEs in the early phase of drug development.A combination of in silico and in vitro approaches provides a basis for robust estimation of the BCS class of NMEs without clinical information and contribute to early selection of biopharmaceutical promissory drug candidates. As a relevant limitation, this data set consists of a small number of drugs. Besides, the uncertainty of the relationship between absorption extent and proposed provisional classification (especially for low absorbed drugs) remains. A modification of BCS classification scheme (particularly for http://sciforum.net/conference/mol2net-1 class II and III) is needed. A further compilation of in vitro permeability data and aqueous solubility may enhance the applicability domain of in silico classifications.Main text paragraph.
